How to define intermediate stage in Hodgkin's lymphoma?

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 111-114

  Gisselbrecht, C ^a   Mounier, N ^a   Andre M ^b   Casanovas, O ^c   Reman, O ^d   Sebban, C ^e   Divine, M ^f   Brice, P ^a   Briere, J ^a   Hennequin, C ^a   Ferme C ^g  

^a SAINT LOUIS HOSPITAL   (France)

^b Centre Hospitalier Notre Dame Reine Fabiola   (Belgium)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e CENTRE LÉON BÉRARD   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Hodgkin's; Localized stage; Lymphoma; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; HODGKIN DISEASE; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; ARTICLE; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 21044454178     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00463.x     Document Type: Conference Paper

References (14)

1. SUTCLIFFE SB, GOSPODAROWICZ MK, BERGSAGEL DE, et al. Prognostic groups for management of localized Hodgkin's disease. J Clin Oncol 1985;3:393-401.
2. GOSPODAROWICZ MK, SUTCLIFFE SB, CLARK RM, et al. Analysis of supradiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 1992;22:859-865.
3. COSSET JM, HENRY-AMAR M, MEERWALDT JH, et al. The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. Eur J Cancer 1992;28A:1847-1850.
4. CARDE P, HAGENBEEK A, HAYAT M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993;11:2258-2272.
5. ENGERT A, SCHILLER P, JOSTING A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608.
6. SPECHT L. Prognostic Factors in Hodgkin's Disease. Semin Radiat Oncol 1996;6:146-161.
7. AISENBERG AC. Problems in Hodgkin's disease management. Blood 1999;93:761-779.
8. MAUCH P, TARBELL N, WEINSTEIN H, et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988;6:1576-1583.
9. SPECHT L, NORDENTOFT AM, COLD S, CLAUSEN NT, NISSEN NI. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 1988;61:1719-1727.
10. MAUCH PM. Controversies in the management of early stage Hodgkin's disease. Blood 1994;83:318-329.
11. HASENCLEVER D, DIEHL V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
12. THOMAS JFC, NOORDIJK EM, RIEUX C, HENNEQUIN C, LYBEERT MLM, GIRINSKY T, VAN T, VEER MB, HENRY-AMAR M. Six cycles of EPVP followed by 36 gy involved-field irradiation vs. no irradiation in favourable supradiaphragmatic clinical stage I-II Hodgkin's disease lymphoma: the EORTC-GELA strategy in 771 patients (H9-F TRIAL) - 20982. Haematology 2004;73(Supp. 65):40, Abstract E11a.
13. FERMÉ CEH, HAGENBEEK A, BRICE P, et al. MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's disease (HD): comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients. Blood 2000;96(Suppl. 11):576a, Abstract 2473.
14. DIEHL V. Chemotherapy or combined modality treatment; the optimal treatment for Hodgkin's disease. J Clin Oncol 2004;22:15-18.